Calfactin, a surfactant therapy, has been investigated for its potential use in treating COVID-19. Early research explored its efficacy in patients with acute respiratory distress syndrome (ARDS) caused by the virus.
How does Calfactin work in ARDS?
Calfactin is a lung surfactant derived from calf lungs. In individuals with ARDS, the lungs' natural surfactant can be depleted or impaired. Surfactant is crucial for reducing surface tension in the alveoli, the tiny air sacs in the lungs. This reduction prevents the alveoli from collapsing, allowing for efficient gas exchange (oxygen entering the bloodstream and carbon dioxide leaving). By administering Calfactin, the aim is to restore the surfactant function, improve lung mechanics, and facilitate breathing in patients with severe respiratory compromise [1].
What were the results of COVID-19 trials with Calfactin?
Studies have examined Calfactin's impact on COVID-19 patients experiencing ARDS. Some research has indicated potential benefits, such as improved oxygenation and reduced need for mechanical ventilation. However, results have varied, and the therapy has not become a standard treatment for COVID-19-related ARDS. Further clinical trials may be needed to definitively establish its role and optimize its application in this context [1].
Are there other surfactant therapies for respiratory conditions?
Yes, other exogenous surfactant preparations are available and used for conditions like respiratory distress syndrome in premature infants. These preparations, like poractant alfa and beractant, are also derived from animal sources and aim to provide the same benefits of restoring lung surfactant function [2]. The application of these in adult ARDS, including that caused by COVID-19, has also been a subject of research.
Where can I find more information on drug patents and exclusivity?
Information regarding drug patents, their expiry dates, and market exclusivity for various pharmaceuticals, including those related to respiratory treatments, can be found on DrugPatentWatch.com [3].
---
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com